| Log in

Kotak PE's Life Sciences Fund Buys 3.4% In Natco Pharma

17 August, 2016

Kotak Private Equity Group, the private equity arm of private sector lender Kotak Mahindra Bank, has acquired 3.4 per cent stake in Hyderabad-based Natco Pharma. Kotak India Venture Fund-I, a life sciences-focused venture fund, has invested Rs 23.7 crore in the recently concluded Rs 67.5 crore qualified institutional placement (QIP) of the pharmaceutical company.

Another major investor in the QIP was Orange Mauritius Investments that already held 2.72 per cent stake in Natco. With the current QIP, it will have around 6-7 per cent stake in the company.

Sun Pharmaceutical promoter Dilip S. Shanghvi is also building stake in Natco, having picked up 3.2 per cent from the markets.

Natco’s QIP was done at a share price of Rs 225 each. Shares of Natco were trading at Rs 242.65 a piece on the BSE at 10:06 am, down 1.34 per cent.

Kotak PE has made life sciences investments in companies like CRO firm SIRO Clinpharm, biopharmaceutical firm Intas, drug discovery player Indus Biotech and biological and bio-pharmaceutical products maker Bharat Serums, among others.

In the past, Kotak PE has invested Rs 54 crore in the QIP of Godrej Consumer Products (July 2010) and Rs 60 crore in the QIP of ING Vysya Bank (June 2011).

For more on Natco’s QIP,click .


Leave Your Comment
Kotak PE starts exiting Natco Pharma with 2x gains

Kotak PE starts exiting Natco Pharma with 2x gains

Madhav A Chanchani 5 years ago
Kotak Private Equity Group, the private equity arm of private sector lender...
Natco Appoints Kotak PE CEO Nitin Deshmukh To Board

Natco Appoints Kotak PE CEO Nitin Deshmukh To Board

Bhawna Gupta 6 years ago
Hyderabad-based Natco Pharma Ltd has appointed Nitin Deshmukh as an additional...
CX Partners to pick 7% stake in Natco Pharma

CX Partners to pick 7% stake in Natco Pharma

Madhav A Chanchani 4 years ago
CX Partners, set up by former Citi Venture Capital International India head Ajay...
No Comments

Kotak PE's Life Sciences Fund Buys 3.4% In Natco Pharma

Powered by WordPress.com VIP